The Centers for Disease Control’s independent advisory committee will meet May 12 for what’s expected to be a discussion of Pfizer’s request to authorize the emergency use of its COVID-19 vaccine on children aged 12 to 15. The Advisory Committee on Immunization Practices will discuss efficacy and safety data that has been under review by the Food and Drug Administration for several weeks. Pfizer, after indicating plans to do so earlier this week, formally filed for full FDA authorization of its vaccine for ages 16 and up. Full approval likely will increase the potential of more employers requiring vaccination.

Related News Articles

Headline
The AHA today joined the Department of Health and Human Services, Centers for Disease Control and Prevention, and other national health care and public health…
Headline
The Health Resources and Services Administration has reimbursed more than 5 million claims to administer COVID-19 vaccine to uninsured individuals, the agency…
Headline
The Centers for Disease Control and Prevention Friday awarded states and other jurisdictions $200 million in supplemental funding from the American Rescue Plan…
Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…